跳至主要内容
临床试验/NCT02379156
NCT02379156已完成4 期

Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia

James J. Peters Veterans Affairs Medical Center1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2015年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Change in Core Body Temperature

研究概览

简要总结

The ability to maintain normal core body temperature (Tcore = 98.6°F) is impaired in persons with a cervical spinal cord injury (tetraplegia). Despite the known deficits in the ability of persons with spinal cord injury (SCI) to maintain Tcore, and the effects of hypothermia to impair mental function in able-bodied (AB) persons, there has been no work to date addressing these issues in persons with tetraplegia.

Primary Aim: To determine if exposure of up to 2 hours to cool temperatures (64°F) causes Tcore to decrease in persons with tetraplegia, and if that decrease is associated with a decrease in cognitive function.

Primary Hypotheses: Based on our pilot data: (1) 66% of persons with tetraplegia and none of the matched controls will demonstrate a decline of 1.8°F in Tcore; (2) 80% of persons with tetraplegia and 30% of controls will have a decline of at least one T-score in Stroop Interference scores (a measure of executive function).

Secondary Aim: To determine the change in: (1) distal skin temperature, (2) metabolic rate, and (3) thermal sensitivity.

Secondary Hypothesis: Persons with tetraplegia will have less of a percent change in average distal skin temperatures and metabolic rate, and report lower thermal sensitivity ratings compared with AB controls.

Tertiary Aim: To determine if a 10 mg dose of an approved blood pressure-raising medicine (midodrine hydrochloride) will (1) reduce the decrease in Tcore and (2) prevent or delay the decline in cognitive performance in the group with tetraplegia compared to the exact same procedures performed on the day with no medicine (Visit 1) in that same group.

Tertiary Hypothesis: Through administering a one-time dose of midodrine, the medicine-induced decreased blood flow to the skin will lessen the decline in Tcore and prevent or delay the associated decline in cognitive performance compared to the changes in Tcore and cognitive performance during cool temperature exposure without midodrine in the same group with tetraplegia.

详细描述

This study will investigate the mechanisms contributing to thermoregulatory fragility in persons with tetraplegia when exposed to cool ambient temperatures that are routinely encountered during their activities of daily living (ADL). Subnormal body core temperatures and vulnerability to hypothermia (Tcore<95°F) have been reported in Veterans with tetraplegia upon exposure to relatively mild environmental temperatures. The impact that a drift in Tcore will be expected to have on cognitive performance, specifically working memory and executive function, will be demonstrated. These 2 areas of cognitive performance are vital for the ability to optimally care for one's self, which persons with higher cord lesions must excel at to ensure health and to attain the maximal degree of independence possible. The one-time administration of an alpha agonist, midodrine hydrochloride, in an attempt to attenuate the drift in Tcore and prevent or delay the expected decline in cognitive performance to exposure to cool on cognitive function will be investigated as well.

Preparation for Study Visits:

The study visits will be at least 1 day apart but no more than 2 weeks apart. Subjects will be provided a light, standard meal which they will be asked to eat 2 hours prior to their scheduled visit time. The meal will be either a plain bagel or 2 pieces of toast. For each visit, subjects will be asked to empty their bladders before their arrival and again upon arrival, if needed. Subjects will be asked to avoid caffeinated and alcoholic beverages and heavy exertion for 24-hours before testing. Subjects will wear minimal clothing (gym shorts, sports bra) during the study to maximize bare skin exposure to the cool temperature.

Visit 1: Cold Ambient Challenge Instrumentation: During the subject's first visit, a thin flexible rectal sensor will be placed 4 inches beyond the anal sphincter for Tcore measurement, and skin thermal sensors will be taped at 15 sites above and below the level of lesion for collection of skin temperature (Tsk). A mask will be placed over the subject's nose and mouth for measurement of exhaled gases from which resting metabolic rate will be calculated from analysis of expired gases (VO2) by a metabolic cart. Laser Doppler flowmetry (LDF) will be used to measure changes in microvascular perfusion by taping a laser doppler probe on the skin in the area of the ulnar styloid processes and medial malleoli bilaterally to confirm vasoconstriction. A pulse oximeter will be placed on the left second digit to obtain blood oxygen saturation and heart rate (HR). An automated blood pressure cuff will be placed above the right elbow to measure brachial blood pressure (BP). An intravenous catheter will be placed in the right antecubital or nearby vein and secured for sequential blood collection for blood hormones (cortisol and norepinephrine).

Baseline Collection: At the end of the 30-minute acclimation period (81°F), a 15-minute baseline (BL) collection of the following measures will be performed: Tcore, Tsk, and VO2 will be measured continuously; BP, HR, blood oxygenation, and thermal sensitivity will be measured at 5-minute intervals; 5 minutes of LDF will be measured at 10-minute intervals; a venous blood draw will be collected once for norepinephrine and cortisol concentrations. At the end of the BL period, a cognitive performance battery will be given.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 68 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Duration of SCI ≥1 year;
  • Level of SCI C3-T1, AIS A & B;
  • Age between 18 and 68 years.

排除标准

  • Evidence of sympathetic integrity below the lesion level by the skin axon-reflex vasodilatation (SkARV) test;
  • Known allergies to midodrine hydrochloride;
  • Past Medical History (PMH) of diagnosed heart, kidney, peripheral vascular, or cerebral vascular disease, or diabetes mellitus;
  • Hypertension (BP>140/90 mmHg);
  • Untreated thyroid disease;
  • Acute illness or infection;
  • Current smoker;
  • Pregnancy.

研究组 & 干预措施

Able-bodied Control Cool Temperature Exposure / No Drug

Other

Subjects are able-bodied (AB) persons, ages 18-65. AB participants were matched to the SCI group by age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).

干预措施: Cool Temperature (Other)

SCI Cool Temperature Exposure / No Drug

Experimental

Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, American Spinal Injury Association Impairment Scale (AIS) levels A and B, ages 18-65 years. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).

干预措施: Cool Temperature (Other)

SCI Cool Temperature Exposure with Drug

Experimental

Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).

干预措施: Midodrine Hydrochloride (Drug)

SCI Cool Temperature Exposure with Drug

Experimental

Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).

干预措施: Cool Temperature (Other)

结局指标

主要结局

Change in Core Body Temperature

时间窗: 120 minutes

We measured the effects of cool temperature (64°F) exposure, of up to 120 minutes, on the ability to maintain a constant Tcore (i.e., Tcore of 98.6°F) in all intervention arms.

次要结局

  • Percent Change in Cognitive Performance - Wechsler Adult Intelligence Scale 4th Edition (WAIS IV)(120 minutes)
  • Change in Distal Skin Temperature (Tsk)(120 minutes)
  • Percent Change in Microvascular Perfusion(Up to 120 minutes)
  • Percent Change in Oxygen Consumption (VO2)(Up to 120 minutes.)

研究者

发起方
James J. Peters Veterans Affairs Medical Center
申办方类型
Fed
责任方
Principal Investigator
主要研究者

John Handrakis, PT, DPT, EdD

Research Health Science Specialist

James J. Peters Veterans Affairs Medical Center

研究点 (1)

Loading locations...

相似试验